Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin

Clinical Drug Investigation

Volumn 19, Issue 5, 2000, Pages 327-334

  Van Dam, Marjel ^a   Basart, Dick C G ^b   Janus, Charles ^b   Zwertbroek, Rolf ^b   Spierenburg, Han A M ^c   Werner, Hans A ^c   Bredero, A C ^d   Lansberg, Peter J ^e   Jonker, Carla J ^f   Trip, Mieke D ^a   Prins, Martin H ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Westfries Gasthuis ^*  (Netherlands)

^c Schieland Hospital   (Netherlands)

^d DEPARTMENT OF SURGERY   (Netherlands)

^e SLOTERVAART HOSPITAL   (Netherlands)

^f Parke Davis BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MYALGIA; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE;

EID: 0034075199     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019050-00002     Document Type: Article

References (30)

1. 1. Adult treatment panel II. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993; 269 (23): 3015-23
2. 2. Adult treatment panel II. High blood cholesterol. Circulation 1994; 89 (3): 1329-445
3. 3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
4. 4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 44: 1383-9
5. 5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
6. 6. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53 (5): 828-47
7. 7. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-33
8. 8. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995 May; 15: 678-82
9. 9. Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a double-masked study. Clin Ther 1996; 18 (5): 853-63
10. 10. Bertolini S, Bittolo Bon G, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130: 191-7
11. 11. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79: 38-42
12. 12. Jonsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17 (7): 1001-7
13. 13. Dart A, Jerums G, Nicholson G, et al. A multicentric, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastalin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44
14. 14. Jones PH, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hvpercholeslerolemia (the CURVES study). Am J Cardiol 1998; 81: 582-7
15. 15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
16. 16. Gonzalez Estrada M, Rodriguea Ferrer CR. Asterlou IR, et al. Use of serum cholesterol/triglycerides ratio to discern for which individuals the Friedewald formula can be used confidently. Clin Chem 1990; 36: 1673-5
17. 17. Siedel J, Hagele ED, Ziegenhorn J, et al. Reagent for the enzymatic determination in serum total cholesterol in serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-80
18. 18. Ellerbe P, Myers GL, Cooper GR, et al. A comparison of results for cholesterol in human serum obtained by the reference method and by the definitive method of the national reference system for cholesterol. Clin Chem 1990; 36: 370-5
19. 19. Cole TG. Glycerol blanking in triglyceride assays: is it necessary. Clin Chem 1990; 36: 1267-8
20. 20. Klotzsch SG, McNamara JR. Triglyceride measurements: a review of methods and interferences. Clin Chem 1990; 36: 1605-13
21. 21. Yagi KA. Simple fluorimetric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15: 212-6
22. 22. Steele BW, Koehler DF, Azar MM, et al. Enzymatic determination of cholesterol in high density lipoprotein fractions prepared by a precipitation technique. Clin Chem 1976; 22: 98-101
23. 23. Lopez-Virella MF, et al. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882-4
24. 24. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham. A statement for Healthcare professionals from the AHA Task Force on Risk Reduction. Circulation 1998; 97: 1876-87
25. 25. Pearson TA, McBride PE, Houston-Miller N, et al. Task Force 8: organization of preventive cardiology service. J Am Coll Cardiol 1996; 27: 1039-47
26. 26. Williams RR, Schumacher MC, Barlow GK, et al. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 1993; 72: 18D-24D
27. 27. McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program Guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158: 1238-44
28. 28. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastalin and recurrent coronary events in the cholesterol and recurrent events trials. Circulation 1998; 81: 578-81
29. 29. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease in the Scandinavian Simvastatin Survival Studv (4S). Circulation 1998; 97: 1453-60
30. 30. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes is saphenous-vein coronary-artery bypass graft. N Engl J Med 1997; 336: 153-62